Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
6 evidence topics · 5 sources
Molecular structure: cetuximab-based anti-EGFR IgG1 antibody fused to the TGF-beta receptor II extracellular domain
Tumor-directed TGF-beta ligand trap
“Ficerafusp alfa (BCA101) is a first-in-class bifunctional antibody that fuses a TGF-β immune-modulating payload or trap to an EGFR tumor antigen–directed antibody for selective delivery to the tumor microenvironment. Ficerafusp alfa aims to target immunosuppressive mechanisms in the tumor microenvironment mediated by TGF-β1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Retained EGFR activity: inhibition of EGFR signaling and antibody-dependent cellular cytotoxicity
“FaDu cells preincubated with either BCA101 or cetuximab and spiked with EGF showed comparable inhibition of EGFR phosphorylation (Tyr1068).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BCA101 showed concentration-dependent ADCC activity in the reporter-based ADCC assay comparable with that of cetuximab (Fig. 2D)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TGF-beta isoform selectivity: TGF-beta1 and TGF-beta3 neutralized, TGF-beta2 spared
Preclinical immune effects and rationale for combination with PD-1 blockade
“BCA101 increased production of proinflammatory cytokines and key markers associated with T-cell and natural killer–cell activation, while suppressing VEGF secretion. In addition, BCA101 inhibited differentiation of naïve CD4+ T cells to inducible regulatory T cells (iTreg) more strongly than the anti-EGFR antibody cetuximab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination of BCA101 and anti-PD1 antibody improved tumor inhibition in both B16-hEGFR–expressing syngeneic mouse models and in humanized HuNOG-EXL mice bearing human PC-3 xenografts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote